Home LiteratureArticle Details
PMID: 2354448 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Reversal of multidrug resistance by lipophilic drugs.

Cancer research ·Vol. 50 ·No. 13 ·1990-07-01 ·Pages 3997-4002

Hofsli E, Nissen-Meyer J

Abstract

The phenomenon of multidrug resistance implies that a wide spectrum of structurally and functionally unrelated chemotherapeutic drugs are recognized and processed by the molecular system which protects multidrug-resistant (MDR) cells against lipophilic cytotoxic drugs. This suggests that lipophilic agents with low toxicity may also be recognized and processed by this molecular system. At high concentrations these agents might saturate the system, thereby reversing multidrug resistance. In support of this hypothesis, 19 (73%) of 26 arbitrarily chosen lipophilic drugs were in this study found to increase the accumulation of actinomycin D in MDR WEHI 164 cells. The most potent of these drugs were also shown to sensitize these cells to the cytotoxic effect of actinomycin D and doxorubicin. There was a good correlation between the ability of the lipophilic drugs to induce an increased accumulation of actinomycin D in MDR cells and their ability to sensitize these cells to the cytotoxic effect of chemotherapeutic drugs. The ability to reverse drug resistance appeared to be additive, since increased accumulation of actinomycin D was also obtained by combining low concentrations of various lipophilic drugs. This may be a way to reduce the in vivo toxic effect of the lipophilic drugs yet still obtain a reversal of drug resistance. When MDR cells were exposed to lipophilic drugs which reversed drug resistance, the synergistic cytotoxic effect of actinomycin D and tumor necrosis factor was obtained at reduced actinomycin D concentrations.

MeSH Terms
Animals Cells, Cultured Dactinomycin/metabolism Dose-Response Relationship, Drug Drug Resistance Drug Synergism Erythromycin/metabolism Lipid Metabolism Mice Pentazocine/pharmacology Tumor Necrosis Factor-alpha/pharmacology Verapamil/metabolism
Chemicals
Tumor Necrosis Factor-alpha Dactinomycin Erythromycin Verapamil Pentazocine
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Hofsli E
Cell Research Laboratory, Institute of Cancer Research, University of Trondheim, Norway.
Nissen-Meyer J
Article Info
Journal
Cancer research
Abbr.
Cancer Res
ISSN
0008-5472
Published
1990-07-01
Pages
3997-4002
Language
English
Region
United States
NLM ID
2984705R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com